Seeking Alpha

Marty Chilberg's  Instablog

Marty Chilberg
184 Followers
25 Following
Send Message
I'm a retired CPA who spent the majority of his working career in technology companies. My work resume included management stints at Atari Inc, Daisy Systems Corp, Symantec Corp and Visio Corp. My last position at Visio (VSIO) was as CFO and VP Finance and Operations.
  • Non-Invasive Prenatal Testing ("NIPT) Market Heating Up 2 comments
    Feb 26, 2013 1:25 PM | about stocks: SQNM

    2013 is looking like a pivotal year for the NIPT market. Sequenom appears to be the market leader with a run rate of 120,000 as of the end of last year. However, this lead is much slimmer than earlier due to increased competition. Genomic sequencing is targeted to be a massive market looking forward and the prenatal space is on the leading edge. The main players in this space are as follows:

    Sequenom - MaterniT21 Plus

    • List $2,700. Reimbursement rate unknown
    • MPSS has higher cost as it looks at more cfDNA fragments
    • Run Rate 120k all high risk and US
    • Covered lives 56m US at 1/13. Target 120m by end of 2013
    • COGS approximately $500

    Ariosa Diagnostics - Harmony

    • List $795. Reimbursement rate unknown
    • Domestic sales/marketing partner LabCorp
    • Targeted sequencing is cheaper as it analyzes fewer fragments
    • Run Rate 100k Dec-12. Virtually all high risk and US.
    • COGS much lower per company.

    Vernita - Verifi

    • List price $1,200. Reimbursement rate unknown
    • MPSS similar to MaterniT21 Plus
    • Domestic sales/marketing partner Perkinselmer
    • Purchased by Illumina recently
    • Run rate unknown. Believed to be distant third

    Natera - Panorama

    • List price $1,495
    • Limited release. Expected widely available end of Mar-13
    • Domestic sales/marketing partner Quest Diagnostics
    • Looks at Single Nucleotide Polymorphisms SNP with informatics
    • Run rate premature. Limited clinical trials/none blind

    Cellscape - Clarity

    • Test not on market. Said to be signing sites for clinical trial
    • Positioning test as a microarray diagnostic test rather than a screen from fetal cells that are pregnancy specific
    • No information on launch target or pricing yet

    Disclosure: I am long SQNM.

    Themes: NIPT, genetic analysis, LDT, prenatal testing Stocks: SQNM
Back To Marty Chilberg's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

This post has 2 comments:

Track new comments on this article
  •  
    Natera does have blinded data. There will be published information regarding Natera's blinded data set in the near future.
    7 Mar, 05:13 PM Reply Like
  •  
    Not a surprise. Comment was meant to say that no blinded results published.
    7 Mar, 06:50 PM Reply Like
Full index of posts »
Latest Followers

StockTalks

  • GTACS vendor awards announced. TSYS one of 20 http://1.usa.gov/SzBDG1
    Nov 1, 2012
  • TSYS must know of or anticipate some specific orders. Hiring in WA, MD, VA, CA. Opened over 60 new positions this quarter.
    Aug 27, 2012
  • Next contract vehicles are Eagle II $22b and GTAC $10b potentials. Awards expected by EOY. TSYS optimistic
    Aug 27, 2012
More »

Latest Comments


Most Commented
Posts by Themes
ABI Research, advertising, advertising sector, Biotechnology, calls, cash flow, China growth stocks, China investing, Chinese growth stocks, CMAS, Commercial Mobile Alerts System, covered calls, cyber security, Defense, Defense sector, defense spending, Diagnostic testing, diagnostic testing, display advertising, E911, free cash flow, Frost Sullivan, genetic analysis, genetics, government sector, GPS, IDC, internet advertising, investing ideas, LBS, LDT, location based advertising, Location based services, location based services, long ideas, Mobile advertising, mobile computing, Mobile display, Mobile search, Networks in Motion, NG9-1-1, NG911, NIPT, options, prenatal diagnostic testing, prenatal testing, PSAP, risk investing, S, securities fraud,
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.